Survival analysis revealed a correlation between elevated MAP3K14 expression and lower survival rates in HCC patients, with significantly lower overall survival (OS), progression-free survival (PFS), and recurrence-free survival (RFS) in patients with high MAP3K14 expression compared to those with low expression. Here, MAP3K14 is linked to hepatocellular carcinoma.